Flexible Flat-Rate Plans
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
DrugPatentWatch Database Preview
EFFEXOR XR Drug Profile
« Back to Dashboard
This drug has eighty-seven patent family members in forty-four countries.
The generic ingredient in EFFEXOR XR is venlafaxine hydrochloride. There are sixty-six drug master file entries for this compound. Seventy-two suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the venlafaxine hydrochloride profile page.
Summary for Tradename: EFFEXOR XR
| Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 19 |
| Drug Prices: : | see details |
Pharmacology for Tradename: EFFEXOR XR
| Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
| Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Clinical Trials for: EFFEXOR XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Pharms Inc | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-001 | Oct 20, 1997 | RX | No | 6,274,171*PED | Sep 20, 2017 | Y | |||||||||||||||||||
Wyeth Pharms Inc | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-003 | Oct 20, 1997 | DISCN | No | 6,274,171*PED | Sep 20, 2017 | Y | |||||||||||||||||||
Wyeth Pharms Inc | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-002 | Oct 20, 1997 | RX | No | 6,274,171*PED | Sep 20, 2017 | Y | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Patents for Tradename: EFFEXOR XR
These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Pharms Inc | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-004 | Oct 20, 1997 | 6,444,708*PED | <disabled> | ||||||||||||||||||||||
Wyeth Pharms Inc | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-001 | Oct 20, 1997 | 4,535,186*PED | <disabled> | ||||||||||||||||||||||
Wyeth Pharms Inc | EFFEXOR XR | venlafaxine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020699-001 | Oct 20, 1997 | 6,310,101 | <disabled> | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: EFFEXOR XR
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| venlafaxine hydrochloride | Extended-release Tablets | 37.5 mg, 75 mg and 150 mg | Effexor XR | 5/3/2007 |
International Patent Family for Tradename: EFFEXOR XR
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norway | 20050379 | <disabled in preview> | |||||||||||||||||||||||||||
| Uruguay | 24613 | <disabled in preview> | |||||||||||||||||||||||||||
| Canada | 2199778 | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
For more information try a trial or see the database preview and plans and pricing
DrugPatentWatch Resources
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639
